Mechanism of ER Protein Misfolding-Induced Mitochondrial Dysfunction

ER蛋白错误折叠引起线粒体功能障碍的机制

基本信息

项目摘要

PROJECT SUMMARY The prevalence of non-alcoholic fatty liver disease (NAFLD) is almost 30% in the western world and is expected to rise in the next decade. NAFLD is characterized by protein misfolding in the endoplasmic reticulum (ER) activating the unfolded protein response (UPR). Prolonged ER stress conditions further lead to oxidative stress, protein aggregation, organelle damage, cellular bioenergetic collapse, and eventually cell death. Recent studies indicate that protein misfolding in the ER contributes to hepatocyte failure associated with NAFLD, non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). Through detailed characterization of hepatocyte function, our preliminary results lead us to propose that ER protein misfolding causes mitochondrial dysfunction that leads to further protein misfolding culminating in hepatocyte failure. Although previous studies demonstrated that protein misfolding in the ER of hepatocytes is associated with metabolic syndrome and NAFLD, there has never been a careful characterization of how ER protein misfolding causes catastrophic cellular events leading to oxidative damage, fibrosis and cell death. We have shown that misfolding of coagulation factor VIII (FVIII) in the ER disrupts complex 1 of the electron transport chain. Amazingly, we demonstrated that treatment with a mitochondrial-targeted antioxidant corrects he defective mitochondrial function and also improves FVIII folding in the ER in cell culture. This unprecedented finding indicates an unappreciated association between ER protein misfolding and defective mitochondrial bioenergetics. In the proposed studies, we will use two separate models to induce ER stress in vivo in hepatocytes; (i) excess nutrition of a high fructose diet, or (ii) expression of FVIII to elucidate how ER protein misfolding disrupts mitochondrial bioenergetics and dynamics. Presently, ongoing clinical studies are using viral delivery of FVIII to hepatocytes in hemophilia A patients. Furthermore, we will apply non-biased technologies of metabolomics and RNA-Seq using novel genetic murine models to elucidate how protein misfolding causes Ca2+ leak from the ER and entry into the mitochondrial matrix to disrupt mitochondrial bioenergetics and/or dynamics. Evidence supports that ER protein misfolding and defective mitochondrial function exist in all degenerative diseases. In addition, extensive findings demonstrate that protein misfolding in the ER is associated with liver failure in a number of common acute conditions including viral infection, ethanol toxicity, acetaminophen toxicity and ischemia reperfusion injury. Our fundamental novel exploration into unchartered territory will undoubtedly generate new hypotheses concerning the impact of ER protein misfolding on the mitochondrial electron transport chain. The studies will provide fundamental mechanistic insight into how ER and mitochondrial functions are reciprocally regulated and lead to novel therapies for NAFLD and other diseases of protein misfolding.
项目摘要 非酒精性脂肪性肝病(NAFLD)的患病率在西方世界几乎为30%, 预计将在未来十年上升。NAFLD的特征是内质网中的蛋白质错误折叠, 内质网(ER)激活未折叠蛋白反应(UPR)。长期的内质网应激条件进一步导致 氧化应激,蛋白质聚集,细胞器损伤,细胞生物能量崩溃,并最终 细胞死亡最近的研究表明,ER中的蛋白质错误折叠有助于肝细胞衰竭 与NAFLD、非酒精性脂肪性肝炎(NASH)和肝细胞癌(HCC)相关。 通过对肝细胞功能的详细描述,我们的初步结果使我们提出ER 蛋白质错误折叠导致线粒体功能障碍,导致进一步的蛋白质错误折叠,最终导致 肝细胞衰竭。虽然以前的研究表明,蛋白质错误折叠在内质网的肝细胞, 与代谢综合征和NAFLD有关,从来没有仔细描述过如何 ER蛋白错误折叠导致灾难性的细胞事件,导致氧化损伤、纤维化和细胞凋亡。 死亡我们已经证明,ER中凝血因子VIII(FVIII)的错误折叠破坏了ER的复合物1, 电子传递链令人惊讶的是,我们证明了用一种靶向肿瘤的治疗方法, 抗氧化剂纠正缺陷的线粒体功能,并改善细胞中ER中的FVIII折叠 文化这一前所未有的发现表明,ER蛋白错误折叠 和线粒体生物能量学缺陷在拟议的研究中,我们将使用两个不同的模型, 在肝细胞中体内诱导ER应激;(i)高果糖饮食的过量营养,或(ii)FVIII的表达 阐明ER蛋白错误折叠如何破坏线粒体生物能量学和动力学。目前, 正在进行的临床研究使用病毒将FVIII递送至血友病A患者的肝细胞。 此外,我们将应用代谢组学和RNA-Seq的无偏见技术,使用新的遗传学方法, 小鼠模型,以阐明蛋白质错误折叠如何导致Ca 2+从ER泄漏并进入 线粒体基质以破坏线粒体生物能量学和/或动力学。有证据表明, 蛋白质错误折叠和线粒体功能缺陷存在于所有退行性疾病中。此外,本发明还提供了一种方法, 广泛的研究结果表明,ER中的蛋白质错误折叠与许多人的肝功能衰竭有关, 常见的急性疾病,包括病毒感染,乙醇中毒,对乙酰氨基酚中毒和缺血 再灌注损伤我们对未知领域的基本探索无疑会产生 ER蛋白错误折叠对线粒体电子传递影响的新假说 链这些研究将为ER和线粒体功能是如何相互作用的提供基本的机制见解。 它调节并导致NAFLD和其他蛋白质错误折叠疾病的新疗法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RANDAL J. KAUFMAN其他文献

RANDAL J. KAUFMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RANDAL J. KAUFMAN', 18)}}的其他基金

Acquisition of Zeiss LSM980 with Airyscan 2, a super-resolution point scanning confocal microscope
购买 Zeiss LSM980 和 Airyscan 2(超分辨率点扫描共焦显微镜)
  • 批准号:
    10632893
  • 财政年份:
    2023
  • 资助金额:
    $ 61.44万
  • 项目类别:
Overcoming FVIII protein misfolding and cell toxicity
克服 FVIII 蛋白错误折叠和细胞毒性
  • 批准号:
    10560541
  • 财政年份:
    2022
  • 资助金额:
    $ 61.44万
  • 项目类别:
Overcoming FVIII protein misfolding and cell toxicity
克服 FVIII 蛋白错误折叠和细胞毒性
  • 批准号:
    10333189
  • 财政年份:
    2022
  • 资助金额:
    $ 61.44万
  • 项目类别:
Mechanism of ER protein misfolding-induced mitochondrial dysfunction
ER蛋白错误折叠导致线粒体功能障碍的机制
  • 批准号:
    9448713
  • 财政年份:
    2017
  • 资助金额:
    $ 61.44万
  • 项目类别:
ER stress and UPR in non-alcoholic steatohepatitis and hepatocellular carcinoma
非酒精性脂肪性肝炎和肝细胞癌中的 ER 应激和 UPR
  • 批准号:
    9914228
  • 财政年份:
    2016
  • 资助金额:
    $ 61.44万
  • 项目类别:
ER stress and UPR in non-alcoholic steatohepatitis and hepatocellular carcinoma
非酒精性脂肪性肝炎和肝细胞癌中的 ER 应激和 UPR
  • 批准号:
    9113989
  • 财政年份:
    2016
  • 资助金额:
    $ 61.44万
  • 项目类别:
ER stress and UPR in non-alcoholic steatohepatitis and hepatocellular carcinoma
非酒精性脂肪性肝炎和肝细胞癌中的 ER 应激和 UPR
  • 批准号:
    9267948
  • 财政年份:
    2016
  • 资助金额:
    $ 61.44万
  • 项目类别:
Homeostatic role of IRE1a-XBP1-PDI1 in hepatic lipid metabolism
IRE1a-XBP1-PDI1 在肝脂质代谢中的稳态作用
  • 批准号:
    8888815
  • 财政年份:
    2015
  • 资助金额:
    $ 61.44万
  • 项目类别:
eIF2a phosphorylation as a novel druggable target in CRPC
eIF2a 磷酸化作为 CRPC 的新型药物靶点
  • 批准号:
    8805370
  • 财政年份:
    2015
  • 资助金额:
    $ 61.44万
  • 项目类别:
Homeostatic role of IRE1a-XBP1-PDI1 in hepatic lipid metabolism
IRE1a-XBP1-PDI1 在肝脂质代谢中的稳态作用
  • 批准号:
    9247167
  • 财政年份:
    2015
  • 资助金额:
    $ 61.44万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 61.44万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 61.44万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 61.44万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 61.44万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 61.44万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 61.44万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 61.44万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 61.44万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 61.44万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 61.44万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了